Why your asthma inhaler is so expensive (in the US)

The blog post discusses the high costs of asthma inhalers in the U.S., examining factors such as the complex pharmaceutical pricing system, patents, the impact of changing drug delivery methods, and the role of pharmacy benefit managers (PBMs). The author highlights how outdated patents on effective treatments, combined with profit-driven strategies by pharmaceutical companies, result in exorbitant prices for patients. The piece outlines the journey from patented brand-name inhalers to generics and authorized generics, ultimately showing how consumers are affected by the disparity in drug prices between the U.S. and other countries.